Xenetic Biosciences(XBIO) - 2025 Q2 - Quarterly Results

Form 8-K General Information This section provides essential identification, contact information, and regulatory filing status for Xenetic Biosciences, Inc Registrant Details This section provides the essential identification and contact information for Xenetic Biosciences, Inc., the entity filing this Form 8-K - Company Name: Xenetic Biosciences, Inc.[2] - Jurisdiction of Incorporation: Nevada[2] - Commission File Number: 001-37937[2] - Principal Executive Offices Address: 945 Concord Street, Framingham, Massachusetts 01701[2] - Registrant's Telephone Number: (781) 778-7720[2] Filing Status and Provisions This part clarifies the specific regulatory provisions under which the Form 8-K is submitted and indicates the registrant's status regarding emerging growth company criteria - The Form 8-K is not intended to simultaneously satisfy filing obligations under Rule 425, Rule 14a-12, Rule 14d-2(b), or Rule 13e-4(c)[3] - The registrant is not an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934[4] Item 2.02 Results of Operations and Financial Condition This section details the announcement of Xenetic Biosciences, Inc.'s financial results for the three months ended June 30, 2025 Financial Results Announcement Xenetic Biosciences, Inc. announced its financial results for the three months ended June 30, 2025, through a press release issued on August 13, 2025, which is incorporated by reference as Exhibit 99.1 - Date of Announcement: August 13, 2025[6] - Period Covered: Three months ended June 30, 2025[6] - Method of Announcement: Press release (Exhibit 99.1 to this Current Report on Form 8-K)[6][7] - The information in this Item 2.02, including Exhibit 99.1, is 'furnished' and not 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, unless expressly set forth by specific reference in a filing[7] Forward-Looking Statements This section provides a cautionary disclaimer for forward-looking statements, outlining their nature, risks, and update policy Disclaimer and Risk Factors This section serves as a cautionary note, indicating that the Form 8-K contains forward-looking statements subject to the safe harbor provisions, outlining their nature, associated risks, and the company's policy on updating such statements - Purpose: Intended to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995[8] - Identification: Statements other than historical facts, identifiable by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates"[8] - Actual activities, performance, achievements, or results may differ materially due to factors described in the "Risk Factors" section of the Company's SEC reports (Form 10-K, 10-Q, 8-K), general market/economic conditions, public health issues, geopolitical events, competitive product development, regulations, manufacturing issues, patent positions, litigation, and shareholder activism[8] - The Company does not undertake any obligation to update forward-looking statements, except as required by law[8] Item 9.01 Financial Statements and Exhibits This section provides a comprehensive list of all documents filed as exhibits to this Form 8-K List of Exhibits This section provides a detailed list of all documents filed as exhibits to this Form 8-K, including the press release announcing financial results and the interactive data file - Exhibit 99.1: Press Release dated August 13, 2025, pertaining to the financial results of the Company for the three months ended June 30, 2025[9] - Exhibit 104: Cover Page Interactive Data File (embedded within the Inline XBRL document)[9] Signatures This section formally concludes the Form 8-K with the signature of an authorized officer Authorized Signatory This section formally concludes the Form 8-K with the signature of an authorized officer, confirming the report's submission on behalf of Xenetic Biosciences, Inc - Registrant: XENETIC BIOSCIENCES, INC.[12] - Signatory: James Parslow[12] - Title: Interim Chief Executive Officer & Chief Financial Officer[12] - Date: August 13, 2025[12]